PATENT CLAIM ANALYSIS

Application Number: 15925996
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["544", "281000"]

Abstract:
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

Claim (Index 76):
The method of  claim 73 , or pharmaceutically acceptable salt thereof, wherein Cy 1  is heteroaryl optionally substituted by 1, 2, 3, 4, or 5 \u2014W\u2014X\u2014Y\u2014Z.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 90.0
- Lexical Diversity: 1.35897
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11942130', '13033918', '12695636', '11834226', '12813148']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8502327533767388
- 35 USC 102 Novelty (BERT): 0.582015143429619
- Combined Prediction Score: 0.8234109923820269
- Mean Citation Score: 475.638744
- Max Citation Score: 503.82446
- Similarity Product: 441.08072875898

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test